Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) Net Margin (2024 - 2026)

Beta Bionics' Net Margin history spans 3 years, with the latest figure at 79.26% for Q1 2026.

  • On a quarterly basis, Net Margin rose 1262.0% to 79.26% in Q1 2026 year-over-year; TTM through Mar 2026 was 60.27%, a 1024.0% increase, with the full-year FY2025 number at 60.6%, up 289.0% from a year prior.
  • Net Margin hit 79.26% in Q1 2026 for Beta Bionics, down from 41.92% in the prior quarter.
  • Over the last five years, Net Margin for BBNX hit a ceiling of 41.92% in Q4 2025 and a floor of 91.88% in Q1 2025.
  • Historically, Net Margin has averaged 65.96% across 3 years, with a median of 64.29% in 2024.
  • The widest YoY moves for Net Margin: up 1721bps in 2025, down -2759bps in 2025.
  • Tracing BBNX's Net Margin over 3 years: stood at 59.13% in 2024, then grew by 29bps to 41.92% in 2025, then tumbled by -89bps to 79.26% in 2026.
  • Business Quant data shows Net Margin for BBNX at 79.26% in Q1 2026, 41.92% in Q4 2025, and 52.14% in Q3 2025.